Table 2 Overall dropout rate and main reasons for treatment discontinuation in real-life studies
Author [ref] | N | duration (months) | Mean ± SD age, years | M/F Ratio | Drop-out rate (%) | Patient decision (%) | Lack of efficacy (%) | Adverse events (%) | Other Causes (%) |
|---|---|---|---|---|---|---|---|---|---|
Molimard et al. 2008 [37] | 146 | 12 | 46.5 ± 13.5 | 0.57 | 30.6 | 1.4 | 19 | 5.4 | 4.8 |
Brusselle et al. 2009 [29] | 158 | 12 | 48.1 ± 17.1 | 0.85 | 45.5 | 10.1 | 13.3 | 12 | 10.1 |
Korn et al. 2009 [34] | 280 | 5 | 43.9 ± 16.3 | 1.45 | 32.5 | NR | 14.28 | NR | NR |
Bavbek et al. 2010 [27] | 18 | 6 | 41.8 ± 11.2 | 0.63 | 0 | NR | NR | NR | NR |
Cazzola et al. 2010 [30] | 142 | 24 | 49.6 ± 4.1 | 1 | 8.5 | 2.11 | 1.4 | 1.4 | 3.5 |
Tzortzaki et al. 2012 [39] | 60 | 26 | 54.0 ± 14.0 | 0.66 | 0 | NR | NR | NR | NR |
Wittchen et al. 2012 [42] | 53 | 24 | 48.3 ± 13.7 | 1 | NR | NR | NR | NR | NR |
Vennera M et al. 2012 [40] | 266 | 15 | 51.0 ± 13.7 | 0.45 | 18.7 | 5.6 | 10.5 | 2.6 | NR |
Lafeuille et al. 2012 [35] | 644 | 24 | 49.9 ± 14.2 | 0.69 | NR | NR | NR | NR | NR |
Eisner et al. 2012 [32] | 4969 | 12 | 44.5 ± 16.6 | 0.56 | NR | NR | NR | NR | NR |
Chen et al. 2013 [31] | 4970 | 48 | 44.5 ± 16.6 | 0.56 | NR | NR | NR | NR | NR |
Grimaldi-Bensouda et al. 2013 [33] | 374 | 36 | 49.7 ± 14.6 | 0.58 | NR | NR | NR | NR | NR |
Barnes et al. 2013 [26] | 136 | 36 | 41.3 ± 14.5 | 0.46 | NR | NR | NR | NR | NR |
Maselli et al. 2013 [36] | 26 | 6 | 29.6 ± 18.7 | 1.6 | 0 | NR | NR | NR | NR |
Group 1a | |||||||||
Maselli et al. 2013 [36] | 26 | 24 | 34.0 ± 17.6 | NR | 0 | NR | NR | NR | NR |
Group 2b | |||||||||
Braunstahl et al. 2013 [28] | 943 | 12 | 45.0 ± 15.5 | NR | 16.6 | 8.4 | NR | NR | 8.2 |
Özgür et al. 2013 [38] | 26 | 6 | 47.6 ± 13.9 | 0.23 | 0 | NR | NR | NR | NR |
Vieira et al. 2014 [41] | 15 | 6 | 45.6 ± 10.8 | 0.15 | 26.66 | 6.66 | NR | 20.00 | NR |
Ancochea et al. 2014 [25] | 214 | 12 | 48.2 ± 17.7 | 0.43 | 7.9 | 4.2 | 2.3 | 1.9 | NR |